06622 ZHAOKE OPHTH-B
- 1.400
- -0.020-1.41%
ZHAOKE OPHTH-B News
Zhaoke Ophthalmology Shrinks Loss in 2023
Zhaoke Ophthalmology (HKG:6622) recorded a decline in attributable loss for the year ended Dec. 31, 2023, to 385 million yuan from 407.3 million yuan in 2022, according to the company's annual report
兆科眼科-B：2023 年報
Zhaoke Ophthalmology-B (06622): Chen Yu resigns as non-executive director
Zhaoke Ophthalmology-B (06622) announced that Chen Yu has resigned as a non-executive director to spend more time on other work arrangements...
Annual Report Observation: The second low-concentration atropine produced in China is coming, and the value of Zhaoke Ophthalmology-B (6622.HK) has been rediscovered
The innovative ophthalmology drug market has always been one of the hot areas that the market has paid great attention to, especially in the field of myopic ophthalmology.
Zhaoke Ophthalmological-B (06622.HK) announces annual results, first confirmation that sales revenue is continuing to expand its footprint globally
Gelonghui, March 27 | Zhaoke Ophthalmology-B (06622.HK) announced that the company first confirmed sales revenue in 2023: in 2023, the company recorded total revenue of RMB 18.8 million, of which RMB 4.7 million came from the sale of ophthalmic drugs (including bemesol timolol and Ruibault), while RMB 8.4 million came from the sale of non-prescription ophthalmic products (Baudexi series hot eye masks). Additionally, the company recorded revenue of RMB 5.6 million from distribution transaction payments outside of China. The company's pipeline is equipped with a variety of key innovative drugs that may have significant curative effects, which can be expected in the future
Zhaoke Ophthalmology-B (06622) announced annual results, net loss of 385 million yuan, a year-on-year decrease of 5.5%
Zhaoke Ophthalmology-B (06622) announced results for the year ended December 31, 2023, and the group achieved revenue...
ZHAOKE OPHTH-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Zhaoke Ophthalmology-B (06622.HK) held a board meeting on March 27 to consider and approve annual results
Gelonghui March 15 | Zhaoke Ophthalmology-B (06622.HK) announced that the board of directors meeting will be held on March 27, 2024 (Wednesday) to consider and approve (among other things) the annual results of the company and its subsidiaries for the year ended December 31, 2023 and their publication.
ZHAOKE OPHTH-B: NOTICE OF BOARD MEETING
Zhaoke Ophthalmology-B (06622) fell 1.80% and now reports 1.670 yuan, a 52-week low
As of 09:20, Zhaoke Ophthalmology-B (06622) is down 1.80% from yesterday's closing price and now reports a 52-week low of $1.670; the trading volume is 0.05 million shares, with a turnover of HK$0.09 million.
Zhaoke Ophthalmology-B (06622) fell 3.40% and now reports 1.730 yuan, a 52-week low
As of 15:11, Zhaoke Ophthalmology-B (06622) fell 3.40% from yesterday's closing price and now reports a 52-week low of $1.730; the trading volume was 740,500 shares, with a turnover of HK$1,318,500.
Zhaoke Ophthalmology-B (06622) fell 11.20% and now reports 1.760 yuan, a 52-week low
As of 14:38, Zhaoke Ophthalmology-B (06622) fell 11.20% from yesterday's closing price and now reports a 52-week low of $1,760; the trading volume was 655,500 shares, with a turnover of HK$1.2038 million.
Zhaoke Ophthalmology-B [06622] now reports HK$1.77, a decrease of 10.61%
As of 14:38, Zhaoke Ophthalmology-B [06622] reported HK$1.77, down 0.21 HK$10.61% from the closing price of HK$1.98, with a turnover of HK$1.1976 million. Today's high price was HK$2.03 and the lowest price was HK$1.77. Based on yesterday's closing price, the 10-day average price was HK$2.58, and the 50-day average price was HK$3.44. The current price-earnings ratio was -2.35 times, and the 14-day strength and weakness index reported 26.50.
At a time of market fluctuations, some opinions on the listing process of Zhaoke Ophthalmology-B (6622.HK) NVK002
As an investor who has been following the innovative medicine sector of Hong Kong stocks for a long time, the Hong Kong stock capital market has continued to be sluggish recently, showing a rare situation of continuous decline. Shareholders have begun to panic, causing many high-quality companies to be affected.
Changes in Hong Kong stocks | Zhaoke Ophthalmology-B (06622) plummeted 31% in the afternoon and previously announced that the FDA designated low-concentration atropine for approval at the end of January
Zhaoke Ophthalmology-B (06622) plummeted 31% in the afternoon. As of press release, it fell 28.43% to HK$2.14, with a turnover of HK$8.7396 million.
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Distribute Eye Drop in Korea
Zhaoke Ophthalmology (HKG:6622) said Zhaoke (Hong Kong) Ophthalmology Pharmaceutical has signed a distribution and supply agreement with South Korea's Kwangdong Pharmaceutical (KRX:009290). The agreem
Changes in Hong Kong stocks | Zhaoke Ophthalmology-B (06622) rose more than 3% to grant exclusive distribution rights for BRIMOCHOL PF in Korea to KDP
The Zhitong Finance App learned that Zhaoke Ophthalmology-B (06622) rose by more than 3%. As of press release, it had risen 3.61% to HK$3.16, with a turnover of HK$1,140,900. According to the news, Zhaoke Ophthalmology announced today that Zhaoke (Hong Kong) Ophthalmology Co., Ltd. (a wholly-owned subsidiary of the company) and Kwangdong PharmaceuticalCo. , Ltd. (KDP, a leading Korean company mainly engaged in pharmaceutical production and distribution) does not contain prophylaxis for BRIMOCHOLPF (2.75% carbaco/ 0.1% bromonidine tartrate 0.1% fixed-dose compound)
Zhaoke Ophthalmology-B (06622.HK): Distribution agreement with KWANGDONG PHARMACEUTICAL for commercialization of BRIMOCHOL PF in Korea
On January 29, Ge Longhui Ophthalmology-B (06622.HK) announced that Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Co., Ltd. (a wholly-owned subsidiary of the Company) and Kwangdong Pharmaceutical Co., Ltd. (“KDP”, a leading Korean company mainly engaged in pharmaceutical production and distribution) have entered into a distribution and supply agreement for BRIMOCHOL PF (2.75% carbaco/ 0.1% bromonidine tartrate) fixed-dose eye drops without preservatives. According to the terms of the agreement, the company has the right to exclusively distribute this product in Korea
Changes in Hong Kong stocks | Zhaoke Ophthalmology-B (06622) rose more than 6% and clinical trial applications for two new drugs to treat presbyopia were approved
Zhaoke Ophthalmology-B (06622) rose more than 6%. As of press release, it rose 6.6% to HK$3.07, with a turnover of HK$1,148,800.
Changes in Hong Kong stocks | Zhaoke Ophthalmology-B (06622) raised 5% in the afternoon to apply for clinical trials of two new drugs to treat presbyopia, approved by the China Drug Administration
The Zhitong Finance App learned that Zhaoke Ophthalmology-B (06622) rose 5% in the afternoon. As of press release, it had risen 5% to HK$2.94, with a turnover of HK$1,090,800. According to the news, Zhaoke Ophthalmology announced that new drug test applications for BRIMOCHOL PF and CARBACHOL PF have recently been approved by China's National Drug Administration. Based on the “Drug Clinical Trial Approval Notice” approved by the State Drug Administration, the company will conduct clinical trials on presbyopia subjects in China. According to the announcement, BRIMOCHOL PF and Carbachol PF are preservative-free
Analysis
Price Target
No Data
